W2O acquired 21GRAMS – a rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human.
Nearly half of lymphoma patients treated with Gilead Sciences Inc.’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to presented data.
Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.
AbbVie Inc. will cease to develop the experimental drug Rova-T after failing to show survival benefit in a late-stage trial for a type of lung cancer.
Internationally recognized healthcare marketing strategy firm 2e Creative joined the Fishawack Group after receiving investment from the global healthcare communications group.
David Lickrish – president, founder and chief executive officer of Highland Therapeutics and Ironshore Therapeutics – spoke with BioSpace about the companies’ Jornay PM (methylphenidate HCL Extended-Release CLL Capsules) and how the new drug fits into the overall ADHD therapeutic market.
Merck & Co. Inc. agreed to buy privately held Tilos Therapeutics for up to $773 million, bolstering the drugmaker‘s pipeline to treat cancer and autoimmune diseases.
Evoke, part of Huntsworth plc, acquired specialty health communications agency KYNE during May 2019.
Evoke, part of Huntsworth plc, announced the acquisition of specialty health communications agency KYNE.
March 20, Horsham, PA — Dudnyk leaders announce the next phase in its evolution as an ever-growing organization by joining The Fishawack Group of Companies. Fishawack is one of the world’s leading independent healthcare communication specialists, with offices in the UK (London, Oxford, Knutsford, Brighton), US (San Diego, Philadelphia), and India. “By joining forces […]